It’s an honor to serve the on-going regulatory training requirements of small to mid-sized clinical research organizations, drug manufacturers, contractors, and professionals seeking to advance rewarding careers within these important sectors.
Paramus, New Jersey (PRWEB)
September 21, 2017
Today, BioPharma Institute, a leading training platform for highly-regulated pharmaceutical and clinical research sector professionals, has announced the addition of 5 new courses to its prospectus. These include the eagerly-awaited Regulation 21 CFR Part 11 training – Compliance with Regulation 21 CFR Part 11 on Electronic Records and Electronic Signatures (Part 11 of Title 21 of the U.S. Code of Federal Regulations for computer systems in FDA-regulated environments). The Institute’s other new courses include Introduction to Drug Safety and Pharmacovigilance, Risk Management Planning for Medicinal Products, How to Gain Approval to Market a Generic Drug in the U.S., and How to Gain Approval for Clinical Trials in the USA. These new courses join the extensive list of programs training on good manufacturing practices (GMP), good laboratory practices (GLP), and good clinical practices (GCP).
Providing many world-class training programs and courses, the BioPharma Institute is trusted by thousands of highly skilled biopharmaceutical industry professionals working in FORTUNE 500 and other corporations in the U.S., plus 10 other countries worldwide. Additionally, Continuing Professional Development (CPD) points for many of its courses are recognized by the distinguished Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom….